FDA warns consumers about Que She
This article was originally published in The Tan Sheet
Executive SummaryFDA warns consumers to stop using the weight-loss capsules Que She and consult health care providers because the product contains undeclared active pharmaceutical ingredients that could endanger people with heart conditions. Undeclared ingredients include the Rx weight-loss ingredient sibutramine, which can increase the risk of heart attack and stroke, and the stimulant fenfluramine, which was removed from the U.S. market in 1997 after studies showed it damaged heart valves. The Rx beta blocker propranolol and the stimulant ephedrine also were found in the capsules and pose a risk to people with heart conditions, FDA said July 8. Principal Deputy Commissioner Josh Sharfstein said removing "spiked" supplements from the market is a priority (1"The Tan Sheet" Oct. 26, 2009)
You may also be interested in...
On this week’s podcast, executive editor Shawn M. Schmitt shares expert tips and advice on how device makers can integrate the recently revised international risk management standard ISO 14971 into their quality systems.
Alpha Tau is looking to change the global radiation therapy paradigm. The Israeli start-up is developing Alpha DaRT, a novel technology for delivering alpha radiation for local tumor destruction.